Vaxxel
Villeurbanne
About Vaxxel
Vaxxel is an Innovative viral live-attenuated platform that develops novel and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumovirus.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.3M
- Funding stage: Seed
- Last round: Seed (Mar 2022)
- Website: vaxxel.fr
- Phone: [email protected]
Industries & Categories
Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/vaxxel-161232 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.